5-Fluorouracil buccal tablets for locoregional chemotherapy of oral squamous cell carcinoma: Formulation, drug release and histological effects on reconstituted human oral epithelium and porcine buccal mucosa

Current Drug Delivery

Volumn 7, Issue 2, 2010, Pages 109-117

  Giannola, Libero Italo ^a   De Caro, Viviana ^a   Giandalia, Giulia ^a   Siragusa, Maria Gabriella ^a   Paderni, Carlo ^a   Campisi, Giuseppina ^a   Florena, Ada Maria ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

5 Fluorouracil; Buccal tablets; Locoregional drug delivery; Oral squamous cell carcinoma; Porcine buccal mucosa; Reconstituted human oral epithelium

Indexed keywords

FLUOROURACIL;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CHEEK MUCOSA; CONTROLLED STUDY; DRUG PENETRATION; DRUG RELEASE; EX VIVO STUDY; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LOW DRUG DOSE; MATRIX TABLET; MOUTH CARCINOMA; MOUTH MUCOSA; NONHUMAN; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; SIMULATION; SQUAMOUS CELL CARCINOMA; STEADY STATE; SWINE; SYSTEMIC CIRCULATION; TABLET FORMULATION; TABLET MATRIX; TISSUE SECTION;

EID: 77950815028     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720110791011792     Document Type: Article

References (32)

1. Hsu, S.; Singh, B.; Schuster, G. Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention. Oral. Oncol., 2004, 40, 461-473. (Pubitemid 38296830)
2. Andreadis, C.; Vahtsevanos, K.; Sidiras, T. 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral. Oncol., 2003, 39, 380-385. (Pubitemid 36379346)
3. Kovacs, A.F.; Turowski, B.; Ghahremani, M.T.; Loitz, M. Intraarterial chemotherapy as neoadjuvant treatment of oral cancer. J. Craniomaxillofac. Surg., 1999, 27, 302-307. (Pubitemid 30103126)
4. Yoshiba, S.; Ito, D.; Nagumo, T.; Shirota, T.; Hatori, M.; Shintani, S. Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G1 phase cell cycle arrest. Oral. Oncol., 2009, 45, 109-115.
5. Li, M.H.; Ito, D.; Samada, M.; Odani, T.; Hatori, M.; Iwase, M.; Naguno, M. Effect of 5-fluorouracil on G1 phase cell cycle regulation in oral cancer cell lines. Oral. Oncol., 2004, 40, 63-70.
6. Takimoto, C.H. The clinical pharmacology of the oral fluoropyridine. Curr. Probl. Cancer., 2001, 25, 134-213.
7. Brown, J.M.; Wilson, W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer., 2004, 4, 437-447.
8. Janssen, H.L.; Haustermans, K.M.; Balm, A.J.; Begg, A.C. Hypoxia in head and neck cancer: How much, how important? Head Neck, 2005, 27, 622-638. (Pubitemid 40961072)
9. Song, X.; Liu, X.; Chi, W.; Liu, Y.; Wei, L.; Wang, X.; Yu, J. Hypoxia induced resistance to cisplatin and doxorubicin in nonsmall cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer. Chemother. Pharmacol., 2006, 58, 776-784. (Pubitemid 44351258)
10. Yang, H.; Zhang, X.; Chopp, M.; Jiang, F.; Schallert, T. Local fluorouracil chemotherapy interferes with neural and behavioural recovery after brain tumor-like mass compression. Behav. Brain. Res., 2006, 172, 80-89. (Pubitemid 44063550)
11. Singh, B.N.; Singh, R.B.; Singh, J. Effects of ionization and penetration enhancers on the transdermal delivery of 5-fluorouracil through excised human stratum corneum. Int. J. Pharm., 2005, 298, 98-107. (Pubitemid 40828331)
12. Loven, K.; Stein, L.; Furst, K.; Levy, S. Evaluation of the efficacy and tolerability of 0.5% Fluorouracil cream and 5% Fluorouracil cream applied to each side of face in patients with actinic keratosis. Clin. Ther., 2002, 24, 990-1000. (Pubitemid 34734743)
13. Levy, S.; Furst, K.; Chern, W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin. Ther., 2001, 23, 901-907. (Pubitemid 32554571)
14. Levy, S.; Furst, K.; Chern, W. A Pharmacokinetic evaluation of 0.5 % and 5% fluorouracil topical cream in patients with actinic keratosis. Clin. Ther., 2001, 23, 908-920. (Pubitemid 32554572)
15. Glavas-Dodov, M.; Fredro-Kumbaradzi, E.; Goacinova, K.; Calis, S.; Simonoska, M.; Hincal, A.A. 5-Fluorouracil in topical liposome gels for anticancer treatment-formulation and evaluation. Acta Pharm., 2003, 53, 241-250.
16. Pather, S.I.; Rathbone, M.J.; Şenel, S. Current status and the future of buccal drug delivery systems. Expert Opin. Drug Deliv., 2008, 5, 531-542. (Pubitemid 351877432)
17. Gal, J.Y.; Fovet, Y.; Adib-Yadzi, M. About a synthetic saliva for in vitro studies. Talanta, 2001, 53, 1103-1115.
18. Giannola, L.I.; De Caro, V.; Giandalia, G.; Siragusa, M.G.; D'Angelo, M.; Lo Muzio, L.; Campisi, G. Transbuccal tablets of carbamazepine: formulation release and absorption pattern. Int. J. Immunopathol. Pharmacol., 2005, 18, 21-31.
19. Giannola, L.I.; De Caro, V.; Giandalia, G.; Siragusa, M.G.; Campisi, G.; Florena, A.M.; Ciach, T. Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features. Eur. J. Pharm. Biopharm., 2007, 65, 238-246. (Pubitemid 46038078)
20. Vergnaud, J.M. Liquid transport controlled release processes in polymeric material: applications to oral dosage forms. Int. J. Pharm., 1993, 90, 89-94.
21. Peppas, N.A.; Sahlin, J.J. A simple equation for description of solute release III. Coupling of diffusion and relaxation. Int. J. Pharm., 1989, 57, 169-172.
22. Gore, A.V.; Liang, A.C.; Chien, Y.W. Comparative biomembrane permeation of tacrine using Yucatan minipigs and domestic pigs as the animal model. J. Pharm. Sci., 1998, 87, 441-447.
23. Jacobsen, J.; van Deurs, B.; Pedersen, M.; Rømer Rassing, M. TR146 cells grown on filters as a model for human buccal epithelium: Morphology, growth, barrier properties, and permeability. Int. J. Pharm., 1995, 125, 165-184.
24. Korsmeyer, R.W.; Gurny, R.; Doelker, E.; Buri, P.; Peppas, N.A. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm., 1983, 15, 25-35. (Pubitemid 13092121)
25. Moharamzadeh, K.; Brook, I.M.; van Noort, R.; Scutt, A.M.; Thornhill, M.H. Tissue-engineered Oral Mucosa: a Review of the Scientific Literature. J. Dent. Res., 2007, 86, 115-124.
26. Dhiman, M.K.; Dhiman, A.; Sawant, K.K. Transbuccal delivery of 5-fluorouracil: permeation enhancement and pharmacokinetic study. APPS PharmSci. Tech., 2009, 10, 258-265.
27. Smart, J.D. Lectin-mediated drug delivery in the oral cavity. Adv. Drug Deliv. Rev., 2004, 56, 481-489. (Pubitemid 38210418)
28. van Eyk, A.D.; van der Bijl, P. Comparative permeability of various chemical markers through human vaginal and buccal mucosa as well as porcine buccal and mouth floor mucosa. Arch. Oral. Biol., 2004, 49, 387-392.
29. Kulkarni, U.; Mahalingam, R.; Pather, S.I.; Li, X.; Jasti, B. Porcine buccal mucosa as an in vitro model: relative contribution of epithelium and connective tissue as permeability barriers. J. Pharm. Sci., 2009, 98, 471-483.
30. Ammar, H.O.; Khalil, R.M. Preparation and evaluation of sustained release solid dispersions of drugs with Eudragit polymers. Drug Dev. Ind. Pharm., 1997, 23, 1043-1054.
31. Rafiee-Tehram, M.; Safaii-Nikui, N.; Peteriet, H.; Beckert, T. Acrylic resins as rate-controlling membranes in novel formulation of a nine-day 17-beta-estradiol transdermal delivery system: in vitro and release modifier effect evaluation. Drug Dev. Ind. Pharm., 2001, 27, 431-437. (Pubitemid 32612732)
32. Grassi, M.; Grassi, G. Mathematical modelling and controlled drug delivery: matrix systems. Curr. Drug. Deliv., 2005, 2, 97-116. (Pubitemid 40590925)